http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103936763-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5383 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5395 |
| filingDate | 2013-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103936763-B |
| titleOfInvention | Oxazolidinone compounds and its production and use |
| abstract | The present invention relates to medical compounds field, more specifically, it is related to a kind of novel oxazolidinone class compound, its enantiomter, diastereoisomer, racemic modification and its mixture, and its pharmaceutically acceptable salt, its preparation method and its purposes as bioactive substance in medicine.The compound of the present invention has very strong anticoagulating active, and it does not influence the activity of fibrin ferment, it is possible to reduce the risk of bleeding.In medicine generation, oral administration biaavailability was far superior to positive control medicine razaxaban it is demonstrated experimentally that the compounds of this invention also has preferable metabolic characteristics. |
| priorityDate | 2013-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 232.